Armada Acquisition Agrees to Merge With Brains Bioceutical
The combined company, to be named Brains Therapeutics, would list common shares on Nasdaq under the ticker BAPI.
Updated on Nov. 6, 2026 in Biotech
Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical, which manufactures active pharmaceutical ingredients and develops pharmaceutical therapies. The deal values Brains Bioceutical at an implied pre-money equity value of about $750 million.
Why it matters
The transaction would take a cannabinoid-focused manufacturer and drug developer public through a special purpose acquisition vehicle, creating a new listed pharmaceutical company. Completion depends on regulatory clearances, registration statements, and shareholder votes from both companies.
The company operates an EU-GMP manufacturing facility through its wholly owned subsidiary BSPG Laboratories and produces or develops cannabinol, cannabidiol, cannabigerol, delta-8-THC, and D9-THC. Its clinical pipeline includes an oral capsule for epilepsy and global rights to an extended-release methazolamide formulation for glaucoma.
The players
Armada Acquisition
Armada Acquisition is a special purpose acquisition company that is merging with Brains Bioceutical to form a publicly listed entity.
Brains Bioceutical
Brains Bioceutical is a company that manufactures active pharmaceutical ingredients and develops pharmaceutical therapies, including cannabinoid products.
The details
Brains Bioceutical is merging into Armada Acquisition, with the combined entity named Brains Therapeutics and listed on Nasdaq under BAPI. The boards of both organizations unanimously approved the transaction, which distributes ingredients across animal health and nutraceutical markets.
Timeline
November 6, 2026: Armada and Brains Bioceutical announce the deal.
Q2 2027: The transaction is scheduled to close and the Nasdaq listing to begin.
The Tech Race
The transaction follows a pattern in which special purpose acquisition companies have been used to list life sciences firms on Nasdaq instead of pursuing traditional initial public offerings. It positions Brains Therapeutics to compete in cannabinoid-derived pharmaceuticals against other companies seeking regulatory approval across multiple jurisdictions.
For investors, the deal offers a route to hold shares in a listed cannabinoid pharmaceutical company once it begins trading as BAPI. Consumers of cannabinoid ingredients and future therapies would see any product changes only after the transaction closes and the business is integrated.
The takeaway
Mergers with special purpose acquisition companies can bring specialized drug developers to public markets faster than traditional offerings, but completion still hinges on regulatory and shareholder approvals. Watch the registration statements and shareholder votes for details on the combined company's finances.
What happens next
The companies must complete regulatory clearances, registration statements, and shareholder votes, with the transaction and Nasdaq listing scheduled for Q2 2027.
Further reading
For broader context on drug development and listings, explore our Biotech coverage.
Source note: This article includes information reported by Pharmaceutical Technology.
